Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 1 Kaplan-Meier estimates of survival free of repeated target site revascularization up to 365 days among patients who received actinomycin-eluting 2.5 and 10 µg/cm2 stents and those who received the metallic stent. The rate of event-free survival was significantly higher in the control stent group than in the actinomycin stent groups (p < 0.05 by both the Wilcoxon and log-rank tests). Solid circles = control (n = 104); open circles = drug-coated, 2.5 µg/cm2 drug-eluting stent (n = 120); squares = drug-coated, 10 µg/cm2 drug-eluting stent (n = 119).
|
